Is Lyell Immunopharma Inc (LYEL) Stock at the Top of the Biotechnology Industry?

The 64 rating InvestorsObserver gives to Lyell Immunopharma Inc (LYEL) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 73 percent of stocks in the Biotechnology industry, LYEL’s 64 overall rating means the stock scores better than 64 percent of all stocks.

LYEL has an Overall Score of 64. Find out what this means to you and get the rest of the rankings on LYEL!

See Full LYEL Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Lyell Immunopharma Inc Stock Today?

Lyell Immunopharma Inc (LYEL) stock is higher by 6.43% while the S&P 500 is down -0.79% as of 2:11 PM on Monday, Sep 26. LYEL has risen $0.41 from the previous closing price of $6.38 on volume of 322,999 shares. Over the past year the S&P 500 is down -17.53% while LYEL is down -47.12%. LYEL lost -$0.96 per share the over the last 12 months. Click Here to get the full Stock Report for Lyell Immunopharma Inc stock.